GFM
TSHA icon

GF Fund Management’s Taysha Gene Therapies TSHA Stock Holding History

GF Fund Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.5K Sell
5,797
-331
-5% -$1.96K ﹤0.01% 418
2026
Q1 		$27.4K Buy
6,128
+745
+14% +$3.46K ﹤0.01% 465
2025
Q4 		$29.6K Sell
5,383
-486
-8% -$2.36K ﹤0.01% 459
2025
Q3 		$19.2K Buy
5,869
+621
+12% +$1.76K ﹤0.01% 494
2025
Q2 		$12.1K Hold
5,248
– – ﹤0.01% 545
2025
Q1 		$7.29K Buy
5,248
+945
+22% +$1.58K ﹤0.01% 598
2024
Q4 		$7.44K Buy
+4,303
New +$8.93K ﹤0.01% 579

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GF Fund Management's TSHA Position: Q2 2026 in Review

GF Fund Management reduced its Taysha Gene Therapies (TSHA) stake by 5.4% in Q2 2026, selling an estimated $1.96K and leaving 5,797 shares worth $39.5K. The position accounts for ﹤0.01% of the portfolio, ranked #418.

GF Fund Management first reported a position in TSHA in Q4 2024 and has held it in 7 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • GF Fund Management held 5,797 shares of Taysha Gene Therapies worth $39.5K as of Q2 2026.
  • GF Fund Management sold 331 Taysha Gene Therapies shares in Q2 2026, an estimated $1.96K.
  • Taysha Gene Therapies made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #418 holding.
  • GF Fund Management first reported a position in Taysha Gene Therapies in Q4 2024 and has held it in 7 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.